0000899243-23-001321.txt : 20230109
0000899243-23-001321.hdr.sgml : 20230109
20230109174834
ACCESSION NUMBER: 0000899243-23-001321
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230105
FILED AS OF DATE: 20230109
DATE AS OF CHANGE: 20230109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KLASKIN CHRISTINE M
CENTRAL INDEX KEY: 0001288123
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29089
FILM NUMBER: 23519128
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGENUS INC
CENTRAL INDEX KEY: 0001098972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 061562417
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-674-4410
MAIL ADDRESS:
STREET 1: 3 FORBES ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIGENICS INC /DE/
DATE OF NAME CHANGE: 19991115
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-05
0
0001098972
AGENUS INC
AGEN
0001288123
KLASKIN CHRISTINE M
C/O AGENUS INC.
3 FORBES ROAD
LEXINGTON
MA
02421
0
1
0
0
PFO & PAO
Common Stock
2023-01-05
4
A
0
31294
2.45
A
153937
D
Stock Option
2.45
2023-01-05
4
A
0
162916
0.00
A
2033-01-05
Common Stock
162916
162916
D
Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
$2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.
Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
/s/ Christine M. Klaskin
2023-01-09